EPCAM and ovarian cancer: The first article in this field was published in 2010, which demonstrated that high-grade, drug-resistant ovarian cancer overexpresses epithelial cell adhesion molecule (EpCAM) and is highly sensitive to immunotherapy using MT201, a fully human monoclonal anti-EpCAM antibody (26).